Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020

$3,495.00

Global Molecular Diagnostics Partnering Terms and Agreements 2014-20209 report provides comprehensive understanding and unprecedented access to the molecular diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2020
Number of pages
450+
Product type
Research report
Available formats
PDF document
Report edition
2
SKU
CP2102mol

The Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.  

 

This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2014.

 

The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.

 

The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 750 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Molecular Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Molecular Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Molecular Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Molecular Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Molecular Diagnostics deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Molecular Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Molecular Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Molecular Diagnostics partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Molecular Diagnostics technologies and products.

 

Key benefits

 

Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Molecular Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2014
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Molecular Diagnostics Partnering Terms and Agreemets 2014-2020 is intended to provide the reader with an in-depth understanding and access to Molecular Diagnostics trends and structure of deals entered into by leading companies worldwide.

 

Molecular Diagnostics Partnering Terms and Agreements includes:

 

  • Trends in Molecular Diagnostics dealmaking in the biopharma industry since 2014
  • Analysis of Molecular Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Molecular Diagnostics deals
  • Access to Molecular Diagnostics contract documents
  • Leading Molecular Diagnostics deals by value since 2014
  • Most active Molecular Diagnostics dealmakers since 2014

 

In Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 750 Molecular Diagnostics deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report provides the reader with the following key benefits:

 

  • In-depth understanding of Molecular Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2014
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Molecular Diagnostics dealmaking

 

2.1. Introduction

2.2. Molecular Diagnostics partnering over the years

2.3. Most active Molecular Diagnostics dealmakers

2.4. Molecular Diagnostics partnering by deal type

2.5. Molecular Diagnostics partnering by therapy area

2.6. Deal terms for Molecular Diagnostics partnering

2.6.1 Molecular Diagnostics partnering headline values

2.6.2 Molecular Diagnostics deal upfront payments

2.6.3 Molecular Diagnostics deal milestone payments

2.6.4 Molecular Diagnostics royalty rates

 

Chapter 3 – Leading Molecular Diagnostics deals

 

3.1. Introduction

3.2. Top Molecular Diagnostics deals by value

 

Chapter 4 – Most active Molecular Diagnostics dealmakers

 

4.1. Introduction

4.2. Most active Molecular Diagnostics dealmakers

4.3. Most active Molecular Diagnostics partnering company profiles

 

Chapter 5 – Molecular Diagnostics contracts dealmaking directory

 

5.1. Introduction

5.2. Molecular Diagnostics contracts dealmaking directory

 

Chapter 6 – Molecular Diagnostics dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Molecular Diagnostics deals by company A-Z

 

Appendix 2 – Molecular Diagnostics deals by stage of development

 

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation

 

Appendix 3 – Molecular Diagnostics deals by deal type

 

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation        

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

 

Appendix 4 – Molecular Diagnostics deals by therapy area

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Molecular Diagnostics partnering since 2014

Figure 2: Active Molecular Diagnostics dealmaking activity– 2014 to 2020

Figure 3: Molecular Diagnostics partnering by deal type since 2014

Figure 4: Molecular Diagnostics partnering by disease type since 2014

Figure 5: Molecular Diagnostics deals with a headline value

Figure 6: Molecular Diagnostics deals with an upfront value

Figure 7: Molecular Diagnostics deals with a milestone value

Figure 8: Molecular Diagnostics deals with a royalty rate value

Figure 9: Top Molecular Diagnostics deals by value since 2014

Figure 10: Most active Molecular Diagnostics dealmakers 2014 to 2020

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events

Pricing options

 

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2bPrecise, 3D BioMed, 3PrimeDx, 10X Genomics, 14M Genomics, 23andMe, A*STAR Agency for Science, Technology and Research, AB Analitica, Abbott Laboratories, Abbvie, Abcam, Abcodia, Abramson Cancer Center, Accelerate Diagnostics, AccuGenomics, AccuRef Diagnostics, AC Immune, Acumen Pharmaceuticals, Adaptive Biotechnologies, ADMA Biologics, Admera Health, ADS, ADT Altona Diagnostic Technologies, Advanced Biological Laboratories, Advanced Cell Diagnostics, Advanced Cooling Therapy, Advanced Genomic Solutions, Advanced Medical German Company of Kuwait, ADx Healthcare, Aetna, Affinium Pharmaceuticals, AFFiRiS, Affymetrix, Agena Bioscience, Agendia, Agilent Technologies, Air Force Research Laboratory, Akers Biosciences, Ako Med, Akonni Biosystems, Akoya Biosciences, Albertsons Companies, Aldeyra Therapeutics, Alere, Allele Biotechnology and Pharmaceuticals, Alliance Global FZ, Alliance Global Group, Almac Diagnostics, Alnylam Pharmaceuticals, Alverno Clinical Laboratories, Alzheimer's Drug Discovery Foundation, Amarantus BioSciences, Ambry Genetics, A Menarini Diagnostics, America's Choice Provider Network, Amgen, Amoy Diagnostics, Amplitech, Anapure BioScientific, Angle, Angsana Molecular & Diagnostics, Anixa Biosciences, Anpac Bio-Medical Science, Anthem Bluecross, Applied BioCode, Arbor Biosciences, Arbor Vita, ArcherDX, Ares Genetics, Ares Life Sciences, Ariosa Diagnostics, Arisan Therapeutics, Arizona State University, AroCell, Arrow Diagnostics, ARUP Laboratories, ASPiRA Labs, Aspira Scientific, Assistance Publique-Hôpitaux de Paris, Astellas Pharma, Asterand Bioscience, Asthma UK, AstraZeneca, Astute Medical, Asuragen, AsureQuality, ATGen Global, Athletigen, Atlas Genetics, Atlas Genomics, Atreca, Atrin Pharmaceuticals, Autobio Diagnostics, AutoGenomics, AUT Roche Diagnostics Laboratory, AUT University, Avant Diagnostics, Avricore Health, Axella Research, Bay Area Lyme Foundation, Bayer, Bayer Healthcare, Baylor College of Medicine, Baylor Genetics, Baylor Miraca Genetics Laboratories, B Braun, B Braun CeGaT, BC Platforms, BD Biosciences, Beckman Coulter, Be Creative Lab, Becton Dickinson, Beijing Genomics Institute (BGI), Beijing Leadman Biochemistry, Berg, Beroni Group, Berry Genomics, Bertech Diagnostics, Be The Match BioTherapies, Bill and Melinda Gates Foundation, Bio-Rad Laboratories, Bio-Techne, BIOASTER, Biocartis, Biocept, BioChain, BioCheck, bioCSL, Biodesix, Biodirection, BioDiscovery, Biodist, Biofidelity, BioFire Diagnostics, BioGemex, Biognosys, Biohealth Innovation, Biohit, BioInvent, Biolidics, Biological Dynamics, Biomatrica, Biomedical Advanced Research and Development Authority, Biomerica, bioMerieux, Biomillenia, BioNano Genomics, BioNova Cientifica, Bioo Scientific, BioPorto, BioReference Laboratories, Biosearch Technologies, BioSure, Biotech-IgG, BioTheranostics, Biovica, BKare Diagnostics, BL&H, BloodCenter Of Wisconsin, Bluebee, Blue Cross Blue Shield Association, BlueCross BlueShield of Tennessee, Blueprint Genetics, Boreal Genomics, Boston IVF, Bostwick Laboratories, Bpifrance, Brahms, Brandeis University, Breath Diagnostics, BridgeCrest Medical, Brigham and Women's Hospital, Brigham Young University, Bristol-Myers Squibb, Broad Institute, Burning Rock, C2i Genomics, C2N Diagnostics, Cambridge Enterprise, Cambridge Epigenetix, Cambridge Isotope Laboratories, Cancer Genetics, Cancer Research Institute, Cancer Research UK, Canon U.S. Life Sciences, Caprion Proteomics, Capsulomics, Cardinal Health, CardioDx, CareDx, CareFirst BlueCross BlueShield, Caris Life Sciences, Carpegen, Case Western Reserve University, CAS Medical Systems, Catholic University Leuven, CBLPath, CeGaT, Celgene, Cellgen Diagnostics, Cell Guidance Systems, Celmatix, Celsee, Celsius Therapeutics, Center for Human Immunology, Autoimmunity and Inflammation, Centers for Disease Control and Prevention, Centogene, Centre Hospital University - Bordeaux, Centre Leon Berard, Cepheid, Cerba HealthCare, Cerveau Technologies, CHDI Foundation, Chembio Diagnostics, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Orange County, Chinese Center for Disease Control and Prevention, Christian Doppler Research Association, Cicero Diagnostics, Cincinnati Children’s Hospital Medical Center, Circulogene, Cirrus Dx, City of Hope, Clarient, Clearbridge Biomedics, ClearLight Diagnostics, Cleveland Clinic, Cleveland Diagnostics, Clinical Genomics, Clinic for Special Children, CloudHealth Genomics, Co-Diagnostics, Cofactor Genomics, Color Genomics, Columbia University, CombiMatrix, Companion Medical, Concile, Congenica, Contextual Genomics, COPAN, CoreBiome, Core Diagnostics India, Corgenix Medical, Coriell Life Sciences, Corona Diagnostics, Cortexyme, Corvida Medical, COTA, Courtagen Life Sciences, Covance, CQuentia, Crossbeta Biosciences, Crown Dental + Medical, CSI Laboratories, CSIRO, Cure Forward, Curetis, Cynvenio, Cypher Genomics, CytoLumina Technologies, D-Eye, d3 Medicine, Daiichi Sankyo, Dako, Daktari Diagnostics, Dana-Farber Cancer Institute, Danish Center for Strategic Research into Type 2 Diabetes, DarioHealth, Dartmouth-Hitchcock Medical Center, DarwinHealth, Debiopharm, DeciBio Consulting, Decipher Biosciences, deCODE Genetics, Defense Threat Reduction Agency, Definiens, Deltex Medical, Denali Therapeutics, Dendreon, Department of Defense, Department of Health and Human Services, Department of Homeland Security, Department of Veterans Affairs, DermTech, DestiNA Genomics, DiaCarta, diaDexus, Diagen, Diagnoplex, Diagnostica Longwood, Diagnostic Oncology Contract Research Organization, Diagnovus, DiamiR, DIAN Diagnostics, DiaSorin, DIAsource ImmunoAssays, Diaxonhit, DNAmito, Domainex, Duke University, DxM Diagnostico Molecular, DxTerity, DySIS Medical, Eastern Ontario Regional Laboratory Association, Eccrine Systems, Edan Diagnostics, Edico Genome, EDP Biotech, Eiken Chemical, EKF Diagnostics, Eleven Biotherapeutics, Eli Lilly, Elucigene, Emerald Organic Growth, Emmes, Emory University, Empire Genomics, Emulate, Endotronix, Enigma Diagnostics, ENSCO, Enterome Bioscience, Enzyvant Science, Epicore Biosystems, Epic Sciences, Epigenomics, Epivax, Erasmus University Medical Center, Ethos Research & Development, Ethos Veterinary Health, Eurobio, EuroClone, Eurofins Scientific, European Commission, European Health Centre Innovation, European Organization for Research and Treatment of Cancer, European Union, Everything Genetic, Evexia Diagnostics, Evogen, Evotec, Exact Sciences, Exagen Diagnostics, Exosome, Exosome Sciences, Expedeon, Expesicor, Expression Analysis, Fast-Track Diagnostics, Feinstein Institute for Medical Research, FetoLumina Technologies, Fianostics, Fio, Five Prime Therapeutics, Florida International University, Fluoresentric, Fluxion Biosciences, FLX Bio, FNApath, Fondation Cancer, Fondatioun Kriibskrank Kanner, FORMA Therapeutics, Fortelinea Software Systems, Fortified Provider Network, Fosun Diagnostics, Fosun Pharmaceutical, Foundation for Innovative New Diagnostics, Foundation Medicine, Fred Hutchinson Cancer Research Center, Freenome, Fudan University, Fujirebio Diagnostics, Fulgent Genetics, Fusion Genomics, Galaxy Health Network, Galectin Therapeutics, GE Healthcare, Gemelli Biotech, Gen-Probe, GENALICE, Genclis, Gencove, Genecast, GeneCentric Therapeutics, GeneDX, GeneInsight, GeneNews, GenePOC, General Electric (GE), GeneThera, Genetic Analysis, Genetic Technologies, Genewiz, Genfit, Genoma, Genome Canada, GenomeDx, Genome Institute of Singapore, Genome Prairie, GenomeSmart, Genomic Health, Genomics England, Genomic Testing Cooperative, Genomind, Genomoncology, George Mason University, Georgia Institute of Technology, German Cancer Research Center, Gestvision, Gibraltar Brothers and Associates, GlaxoSmithKline, GLG Pharma, Global Biological Standards Institute, Global Cancer Diagnostics, Global Genomics Group, Globavir Biosciences, Gloval Specimen Solutions, Glycotest, GNS Healthcare, GNYHA Services, Goffin Molecular Technologies, Good Start Genetics, Government of Canada, Grail, Great Basin Scientific, Greater New York Hospital Association, Group K Diagnostics, Grupo Ferrer, Guardant Health, Gyros Protein Technologies, Hackensack Meridian Health, HalioDx, Harvard Medical School, Harvard University, HEALTH Biomed, HealthTrust, Heat Biologics, Hebrew University of Jerusalem, Helix, Helix2, Helomics, HemaTone, HemoShear, Henry Schein, Hesperos, HiberGene Diagnostics, Highmark Blue Shield, Hitachi High-Technologies Corporation, HMicro, Hoag Memorial Hospital Presbyterian, Horizon Discovery, Hospital of University of Strasbourg, HTG Molecular Diagnostics, Hubrecht Organoid Technology, Hudson Robotics, Human Longevity, Hummingbird Diagnostics, Hvidovre Hospital, hVIVO, Hy Laboratories, I-MED Pharma, Ibex Medical Analytics, iBIO Institute’s PROPEL Center, IBL America, Icahn School of Medicine at Mount Sinai, Icon, Idaho Urologic Institute, IDbyDNA, Idengene, iGenomix, Illumina, ImaginAb, Imec, Imegen, Immucor, ImmuMetrix, ImmunArray, Immunexpress, ImmunID Technologies, ImmunoCellular Therapeutics, Immunovia, Imperial College London, IncellDx, InDevR, Indica Labs, Indivumed, Inflammatix, Informed Data Systems, InGen BioSciences, Inhibrx, Inivata, Innovate UK, Innovation Skane, Inova Health System, Inova Labs, Inova Translational Medicine Institute, Inserm, Inserm Transfert, Insight Genetics, InstantLabs, Institut Català d'Oncologia, Institut Curie, Institute for Bioscience and Biotechnology Research, Institute for Genome Statistics and Bioinformatics, Institute for Systems Biology, Institute of Biophysics, Institute of Cancer Research, Institute of Human Genetics, Institut Gustave Roussy, Instituto Diagnostico Varelli, Institut Pasteur, IntegraGen, Integrated Biobank of Luxembourg, Integrated Diagnostics, Integrated DNA Technologies, Intelligence Advanced Research Projects Activity (IARPA), Intensity Therapeutics, Interlab INTERAUTOMATIKA UAB, Interleukin Genetics, Intermountain Healthcare, Interpace Diagnostics, Interpace Diagnostics Group, InterSystems, Invitae, InVivoScribe, ION Solutions, Ironwood Pharmaceuticals, IRX Therapeutics, IsoPlexis, ISOThrive, Itus, IviGen, JAJ International, Janssen-Cilag, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Jeffrey Modell Foundation, Johns Hopkins University, Johnson & Johnson Innovation, John Wayne Cancer Institute, Kaiser Foundation Research Institute, Kaiser Permanente, Kapa Biosystems, Karolinska Institute, KEW, Kim & Friends, Kindstar Globalgene Technology, Kite Pharma, Knight Cancer Institute, Knight Diagnostic Laboratories, KromaTiD, Kurabo, Kura Oncology, Labcyte, Lab Genomics, Laboratory Corporation of America, LamdaGen, Lantheus Holding, Lee Moffitt Cancer Center, Leica Biosystems, Leicester University, LEO Pharma, Les Laboratoires Servier, LexaGene, LGC, LifeLabs Medical Laboratory Services, LifeX Ventures, Li Ka Shing Foundation, LineaRx, LI Path, Lucid Diagnostics, Luminex, LumiraDx, Lumora, Lunatus, Lund University, Lung Cancer Alliance, Macrogen, Magenta Therapeutics, MagnaChip Semiconductor, Mammoth Biosciences, Manhattan Scientifics, Mannin Research, Marina Biotech, Massachusetts General Hospital, Massachusetts Institute of Technology, Maverix Biomics, Mayo Clinic, MBio Diagnostics, McMaster University, MD Anderson Cancer Center, MDL Information Systems, MDNA Life Sciences, MDxHealth, med fusion, MEDIAN Technologies, Medical University of Graz, Medical University of Innsbruck, Medical University of South Carolina, Medical University of Vienna, MediCare International, MediSapiens, Medison, Medline Industries, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Serono, Meridian Bioscience, Metabiomics, Metabolon, Metafora Biosystems, Metamark Genetics, MetaStat, MGI Pharma, Miacom Diagnostics, Michael J Fox Foundation, Microbiologics, Microbix Biosystems, MicroConstants, Micromedic Technologies, Microsoft, Mikrogen, Mimetas, MiNDERA, Minomic, MIODx, Miraca, Miraca Life Sciences, Miragen Therapeutics, MiRXES, MIT, MiTest Health, Mobidiag, Molbio Diagnostics, Moldionics, MolecularMD, Molecular Stethoscope, Molecular You, Molnlycke Health Care, Mologic, Moores Cancer Center, Movember Foundation, MRIGlobal, MRM Proteomics, MultiPlan, Multiple Myeloma Research Foundation, Myeloma Health, Myelopro Diagnostics and Research, My Gene Counsel, Myriad Genetics, Myriad RBM, N-of-One, NanoMab Technology, Nanommune, nanoMR, Nanopharmacia, Nanosphere, NanoString Technologies, NantHealth, Natera, National Cancer Centre Singapore, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Institute for Communicable Disease Control and Prevention (China), National Institute for Public Health and the Environment, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Standards and Technology, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Kidney Registry, National Science Foundation, Navidea Biopharmaceuticals, Nektar Therapeutics, Neogen, Neogenomics, NEO New Oncology, Nestle Health Science, NetScientific, New England Biolabs, New Horizon Health, New York Genome Center (NYGC), New York University, Next Gen Diagnostics, NextGxDx, Nippon Genetics Europe, NM Genomix, Norgine, NorthBay Healthcare, Northwestern University, Notable Labs, Novartis, Novation, NovellusDx, Novigenix, Novogene, Nucleai, NuProbe, NuView Life Sciences, NX Prenatal, Oligomerix, OmniSeq, Oncgnostics, Oncimmune, OncoCyte, OncoDNA, OncoGenesis, Oncotest, One BioMed, One Lambda, Ontario Institute for Cancer Research, Ontera, Opentrons Labworks, OpGen, OPKO Health, Orebro University, Oregon Health Sciences University, ORIG3N, Origin Biosciences, Ortho-Clinical Diagnostics, Oslo University Hospital, Oswaldo Cruz Foundation (Fiocruz), Otsuka, OvaGene Oncology, Ovarian Cancer Institute, Owlstone Medical, Oxford Biomedical Research Centre, Pain Therapeutics, PapGene, Parabase Genomics, Paradigm, Paris Descartes University, Partners HealthCare, PathGroup, Pathway Diagnostics, Pathway OME, Paul G Allen Family Foundation, PAVmed, Pax Neuroscience, PBL Assay Science, PeptiDream, PerkinElmer, Personal Genome Diagnostics, Personalis, Personalized Medicine Initiative (PMI), PersonalizeDx, Perspectum Diagnostics, Perthera, Pfizer, Phadia, Pharmaco-Kinesis, Pharmacological research Institute Mario Negri, Phase Genomics, Phi Life Sciences, Philips, Phoenix Molecular Designs, Physician’s Choice Laboratory Services, PierianDx, Planet Innovation, Pohang University Of Science And Technology, Population Genetics Technologies, PositiveID, PPD, Precipio Diagnostics, Precision for Medicine, Predicine, PredictImmune, Predictive Technology Group, PrediLife, Premaitha Health, Premas Life Sciences, Premier Inc, Prenetics, Preora Diagnostics, Prescient Medical, Pressure BioSciences, Prevencio, Prime Health Services, Primetech, Probiodrug, Progenetics, Proove Biosciences, Propper Manufacturing, Prosenex, Protagen, Protea Biosciences, Protean BioDiagnostics, Provista Diagnostics, Psyche Systems, Pure MHC, PWNHealth, Pyrobett, Q2 Solutions, Qiagen, Quadrant Biosciences, Quanterix, QuantumDx, Queensland University of Technology, Quest Diagnostics, Quidel, Quintiles, QuiO Technologies, Quotient, Qura Therapeutics, Rabin Medical Center (Beilinson Hospital), Radboud University Nijmegen Medical Centre, Rady Children's Institute for Genomic Medicine, Rainbow Genomics, Rapid Micro Biosystems, Raptor Pharmaceutical, Rebiotix, RedHill Biopharma, RedPath Integrated Pathology, Renji Hospital, Renovar, Repertoire Genesis, Reproductive Health Science, Research Center for Molecular Medicine of the Austrian Academy of Sciences, ResearchDx, Resolution Bioscience, Response Genetics, rEVO Biologics, RevoluGen, Rheonix, Rice University, Righton, Roche, Roche Diagnostics, Roka Bioscience, Rosetta Genomics, Roswell Biotechnologies, Roswell Park Cancer Institute, Royal Marsden Hospital, Royal Philips Electronics, RTI International, Rutgers University, SAGA Diagnostics, Sanford Guide, Sanofi, Sarah Cannon Research Institute, Sarepta Therapeutics, Sayre Therapeutics, Scienion, Sciex, SC Liver Research Consortium (SCLRC), Seattle Genetics, Seegene, Selexis, Sema4, SEngine Precision Medicine, Senova Systems, SenzaGen, Sequenom, Seracare Life Sciences, Serametrix, Shanghai Fosun Long March Medical Science, Sherlock Biosciences, Shire Human Genetic Therapies, Siemens Healthcare, Siemens Healthineers, Signal Genetics, Silicon Biosystems, Singlera Genomics, Singulex, Sino Biological, Sintact Medical Systems, Skane University Hospital, SkylineDX, Skyline Medical, Small Business Innovation Research, SomaLogic, Sonic Healthcare, Sonora Quest Laboratories, Sony DADC, Sophia Genetics, Sorgente, Sorrento Therapeutics, SouthGenetics, Southwest Gynecological Pathology Lab, Spectrum Health, SpeeDx, SpePharm, Sphingotec, SQI Diagnostics, SRI International, STADA Arzneimittel, Standard Process, Stanford University, Stanford University School of Medicine, State of New Jersey, StatSure Diagnostic Systems, StemCyte, St Georges University of London, Strain Genie, Stratify Genomics, Stratose, Streck Laboratories, Sunnybrook Research Institute, Svar Life Science, SweLife, Swift Biosciences, SYGNIS Pharma, Symbiotix Biotherapies, Synlab, Syracuse University, Sysmex, Sysmex Inostics, Systec, T2 Biosystems, Tabula Rasa HealthCare, TaiRx, TaiRx US, Take2, Takeda Pharmaceutical, Tangen Biosciences, Targos, Tebu-Bio, Tecan, Technology Strategy Board (UK), Tempus, Tesaro, Teva Pharmaceutical Industries, Texas A&M University, The National Football League, The Parker Institute For Cancer Immunotherapy, Thermo Fisher Scientific, Thiel Foundation, Thomas Jefferson University, Three Rivers Provider Network, TNK Therapeutics, Todos Medical, Toronto Innovation Acceleration Partners, Tor Vergata University Hospital, Toulouse University Hospital, Transcriptome Sciences, Transgenomic, Translational Drug Development, Translational Software, Transplant Genomics, TrovaGene, True Diagnostics, TTP Group, Tuberous Sclerosis Alliance (TS Alliance), Turgut Ilaclari, Tymora Analytical Operations, uBiome, Ubiquitome, UK Government, UK NEQAS, Uman Diagnostics, Unified Women's Clinical Research, Unilabs, UniQuest, UnitedHealthcare, United States Agency for International Development, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University Hospital of Leuven, University Hospitals Case Medical Center, University Medical Center Hamburg-Eppendorf, University of Arkansas, University of Bonn, University of Bristol, University of British Columbia, University of California, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cincinnati, University of Colorado Denver, University of Greifswald, University of Guelph, University of Leeds, University of Manchester, University of Maryland, University of Melbourne, University of Miami, University of Michigan, University of Minnesota, University of North Carolina, University of Oxford, University of Pennsylvania, University of Rochester, University of Rostock, University of Texas Medical Branch, University of Tokyo, University of Toronto, University of Washington, UPMC, Urology Centers of Alabama, Urology San Antonio, USC Norris Comprehensive Cancer Center, US Department of Commerce, US Oncology, US Oncology Research, Vanderbilt-Ingram Cancer Center, Vantari Genetics, Varian Medical Systems, Ventana Medical Systems, Veracyte, Veravas, VerdePharmHealth, Verinata Health, Veritas Genetics, Vermillion, Viatar CTC Solutions, Vigilant Biosciences, Vikor Scientific, ViraCor Laboratories, Viravaxx, Vir Biotechnology, Viroclinics Biosciences, Vitatex, ViveBio, VolitionRX, VU Medical Center, Weill Cornell Medical College, Welgene Biotech, Wellcome Trust, Wellcome Trust Sanger Institute, Wellgistics, Wuhan Kindstar Diagnostics, Wuxi Apptec Laboratory Services, WuXi NextCODE Genomics, WuXi PharmaTech, Wyss Institute, X4 Pharmaceuticals, Xagenic, XCR Diagnostics, Xylonix, Yale University, Ymir Genomics, Zenon Biosystem, Zenosense, ZenTech, Zenyaku Kogyo, ZoBio, Zomedica, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!